Adbry
| Chemical Name | tralokinumab-ldrm |
| Dosage Form | Injection (subcutaneous; 150 mg/mL) |
| Drug Class | Monoclonal antibodies |
| System | Skin |
| Company | LEO Pharma |
| Approval Year | 2021 |
Indication
- For the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable